ANTI-MUC16-CD3 AMPHIBIOUS ANTIBODIES AND ANTI-MUC16 DRUG CONJUGATES
CY1126307T1Undetermined Publication Date: 2026-07-31REGENERON PHARMACEUTICALS INC
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- CY20231100528T
- Authority / Receiving Office
- CY · CY
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2017-09-14
- Filing Date
- 2023-09-28
- Publication Date
- 2026-07-31
- Estimated Expiration
- 2043-09-28
Abstract
The present disclosure provides anti-mucin 16 antibodies: bispecific antibodies (bsAbs) that bind to both MUC16 and CD3 and activate T cells via the CD3 complex in the presence of tumors expressing MUC16. human lgG antibodies that bind to human and MUC16 (monospecific antibodies). anti-MUC16 antibody drug conjugates that inhibit tumor growth in vivo. The antibodies are useful for the treatment of various cancers, including ovarian cancer.
Need to check novelty before this filing date? Find Prior Art